INS and type 2 diabetes mellitus: This approach is encouraged by the latest development in antidiabetic non-insulin drugs that have had proven benefits for weight, blood pressure (BP), metabolic equilibrium, and lipids metabolism, alongside other pleiotropic effects, which constitute the primary alternatives of the standard-of-care treatment for T2DM [14].